Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Endometrial Advancement After Rec or u-HCG Triggering

This study has been completed.
Sponsor:
Collaborator:
Merck Serono International SA
Information provided by (Responsible Party):
Papanikolaou Evangelos, Universitair Ziekenhuis Brussel
ClinicalTrials.gov Identifier:
NCT00953628
First received: August 5, 2009
Last updated: December 1, 2015
Last verified: December 2015

August 5, 2009
December 1, 2015
August 2005
December 2006   (final data collection date for primary outcome measure)
endometrium histology on the day of OPU [ Time Frame: day of oocytre pick up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00953628 on ClinicalTrials.gov Archive Site
pregnancy rate [ Time Frame: 14 days after oocyte pick up ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Endometrial Advancement After Rec or u-HCG Triggering
Endometrial Advancement After Rec or u-HCG Triggering
The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.
Biopsies of endometrium were taken in different groups Pregnancy rates were compared among defferent groups
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Infertility
  • Drug: 10000 IU urinary HCG
    bolus 10000 units for ovulation triggering
    Other Name: Pregnyl
  • Drug: 250 mcg recombinant HCG
    bolus 250 mcg for ovulation triggering in IVF patients
    Other Name: Ovitrelle
  • Active Comparator: o Group A=uHCG ovul trig
    HCG for triggering
    Intervention: Drug: 10000 IU urinary HCG
  • Experimental: o Group B=recHCG ovul trig
    recombinant HCG for triggering
    Intervention: Drug: 250 mcg recombinant HCG
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
130
December 2008
December 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Less than 36 years old
  • Male or tubal infertility
  • FSH<12 on day 3

Exclusion Criteria:

  • Endometriosis stage 3 & 4
Female
20 Years to 36 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00953628
recHCG001
No
Not Provided
Not Provided
Papanikolaou Evangelos, Universitair Ziekenhuis Brussel
Universitair Ziekenhuis Brussel
Merck Serono International SA
Study Director: Paul Devroey, Professor Professor or OB-GYN
Universitair Ziekenhuis Brussel
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP